LGLaura Giugliano

Laura Giugliano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Giugliano has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Evangelista

    Unit of Clinical Epidemiology, Città della Salute e della Scienza di Torino Turin Italy

    2 shared publications
  • Michele Pinon

    Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital Azienda Ospedaliera‐Universitaria Città della Salute e della Scienza Turin Italy

    2 shared publications
  • Pier Luigi Calvo

    Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital Azienda Ospedaliera‐Universitaria Città della Salute e della Scienza Turin Italy

    2 shared publications
  • Pier Luigi Calvo

    Pediatric Gastroenterology Division, Regina Margherita Children’s Hospital, 10126 Turin, Italy

    2 shared publications
  • Alessandra Coscia

    Neonatology Unit, Department of Public Health and Pediatrics, University of Turin, 10124 Torino, Italy

    1 shared publication
  • Alice Ponte

    Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital Azienda Ospedaliera‐Universitaria Città della Salute e della Scienza Turin Italy

    1 shared publication

Latest Publications

  • Open Access

    Impact of cystic fibrosis transmembrane conductance regulator modulator therapies on liver stiffness and liver enzymes: An observational perspective single‐center cohort study

    by Laura Giugliano, Elisabetta Augustoni, Antonio Pizzol, Anna Opramolla, Cristina Chiadò, Anna Zagaria, Irene Esposito, Giulia Roberto, Alice Ponte, Andrea Evangelista, et al.

    Objectives: The efficacy of cystic fibrosis transmembrane conductance regulator ( CFTR )‐modulator therapies in preventing or ameliorating cystic fibrosis liver disease (CFLD) by correcting CFTR in cholangiocytes is not well‐documented. This study aimed to assess liver function during CFTR‐modulators. Methods: Patients eligible to start Elexacaftor/Tezacaftor/Ivacaftor (July 2021–December 2022), followed‐up at the Piedmont Cystic Fibrosis reference Centre of the Città della Salute e della Scienza, Turin , Italy , were enrolled through a prospective single‐center cohort study and evaluated using hematological exams and liver stiffness measurement (LSM) before treatment and at 1, 3, 6, and 12 months thereafter. The treated group was compared to a group of untreated people with cystic fibrosis (pwCF), evaluated at baseline and after 12 months. Results: Sixty‐nine treated pwCF, mean age 16.0 years, 51% males, were compared to 130 non‐treated pwCF, mean age 12.14 years, 49% males. Treated pwCF were classified by LSM as normal (7 kPa) ( N = 9, 13%). A significant trend in LSM reduction was observed at Month 12 in the subgroups with LSM 5–7 kPa and LSM > 7 kPa (−1.05, p = 0.016 and −1.57, p = 0.022, respectively). PwCF without fibrosis at baseline and non‐treated pwCF showed no LSM change over time. Liver enzyme levels increased at Month 12, trend mirrored in non‐treated pwCF for AST level, remaining within normal ranges. Conclusions: During treatment, a significant LSM reduction was observed in pwCF with liver fibrosis at baseline, especially after Month 1. This rapid improvement could be multifactorial and may suggest a potential early response without significant liver toxicity.

  • Effects of CFTR modulator therapies on liver stiffness and bile flow: A single-centre experience

    by Pier Luigi Calvo, Laura Giugliano, Andrea Evangelista, Elisabetta Bignamini, Michele Pinon


  • COVID-19 as a Trigger of Acute-on-Chronic Hepatitis B Presenting With Undetectable INR Due to Hypercoagulability in a 16-Year-Old Girl

    by Laura Giugliano, Michele Pinon, Pier Luigi Calvo

    In patients with SarS-CoV2 and chronic Hepatitis B (HBV) co-infection liver injury is associated with a worse prognosis. We report a case of acute chronic liver failure (ACLF) with encephalopathy due to HBV reactivation during COVID-19 with undetectable INR. Thromboelastography showed a profile consistent with a prothrombotic state so INR was not a reliable marker of liver function until plasma infusion. After plasma infusion, indeed, an imbalance of hepatic function was shown by an underlying INR prolongation that was consistent with an ACLF.


  • Open Access

    Timely Birth Dose Vaccine to Prevent Vertical Transmission of Hepatitis B: A Single Center Experience on the Road to the WHO Elimination Goals in Italy

    by Michele Pinon, Laura Giugliano, Emanuele Nicastro, Omar Kakaa, Alessandra Coscia, Caterina Carbonara, Lorenzo D’antiga, Pier Luigi Calvo

    Italy was one of the first industrialized countries to implement a program of routine vaccination against hepatitis B virus (HBV) infection. However, currently, no HBV vaccine is administered at birth if the screened mother is HBsAg negative, whilst babies born to HBsAg positive mothers are given vaccine and hepatitis B immunoglobulin, within 12–24 post-delivery hours. A single center retrospective analysis of policies and practices to prevent mother-to-child transmission of HBV was carried out, to evaluate their adherence to HBV care guidelines. Paired maternal-infant medical records for consecutive live births, between January 2015 and December 2019, were reviewed at the AOU Città della Salute e Scienza di Torino, where a total of 235/35,506 babies (0.7%) were born to HBsAg positive mothers. Markers of active viral replication, i.e., HBV DNA level and/or HBeAg, were reported in only 66/235 (28%) of the mothers’ medical records. All newborns had immunoprophylaxis at birth: 61% at 36 h. In 2019, two cases of vertical HBV transmission occurred, despite timely immunoprophylaxis, as their mothers’ viral load was detected too late for antiviral prophylaxis. Missed early identification of pregnant women with high viremia levels or late vaccinations may contribute to perinatal HBV infection. Immunoprophylaxis should be given to babies born to HBsAg positive mothers at the latest within 12 h. In Italy, policies aimed at achieving the WHO 2030 goal of eliminating viral hepatitis should be further implemented.